Roth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32

Benzinga Newsdesk www.benzinga.com Neutral 49.7%

Neg 0% Neu 49.7% Pos 0%

Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $32.